Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates
This article was originally published in PharmAsia News
Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.
You may also be interested in...
Deal is the historically oncology-focused Infinity's first pipeline-building move since it began a strategic alliance with Purdue Pharma and the latter's European affiliate Mundipharma in late 2008.
Intellikine is developing a group of compounds capable of selectively inhibiting different PI3K isoforms. It can mix and match components to achieve a variety of therapeutic goals. The company's lead program, an mTOR inhibitor for cancer, is nearing the clinic. The start-up also sees significant potential for its PI3 kinase inhibitors in inflammatory diseases and hopes to begin a Phase I trial in that area next year.
“Nonprescription Drug Product with an Additional Condition” for OTC use proposed rule would add to drug firms’ workloads for some OTC switches. Along with NDAs, sponsors would need to show a DFl isn’t sufficient to ensure a consumer can appropriately self-select and use a drug OTC and how an “additional condition” system would work.